Related Experiment Video

Updated: May 29, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

[Hypertension, obesity, erectile dysfunction. What kind of drug to choose]

M L Maksimov, A S Ermolaeva, O V Dralova

    Kardiologiia
    |September 1, 2011
    PubMed

    Insights

    Valsartan effectively treats hypertension, a common cardiovascular disease linked to the renin-angiotensin-aldosterone system. This medication shows benefits in patients with hypertension, obesity, and erectile dysfunction.

    Area of Science:

    • Cardiovascular Medicine
    • Pharmacology

    Context:

    • Hypertension is a prevalent cardiovascular disease.
    • Renin-angiotensin-aldosterone system (RAAS) overactivation drives hypertension.
    • ACE inhibitors and Angiotensin Receptor Blockers (ARBs) are key treatments.

    Purpose:

    • To evaluate the effectiveness and organ-protective properties of valsartan.
    • To assess valsartan's tolerability in specific patient groups.

    Summary:

    • Valsartan, an ARB, demonstrates significant hypotensive and organ-protective effects.
    • Pharmacological actions include neurohumoral modulation, antiproliferative effects, and improved endothelial function.
    • The study highlights valsartan's benefits in hypertensive patients with obesity and erectile dysfunction.

    Impact:

    • Provides evidence for valsartan's efficacy in complex hypertensive cases.
    • Supports the use of ARBs for comprehensive cardiovascular disease management.
    • Contributes to understanding treatment strategies for comorbid conditions in hypertension.

    Related Concept Videos

    Drug Dosing: Obese Patients01:21

    Drug Dosing: Obese Patients

    In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
    Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

    Hypertension IV: Drug Therapy and Lifestyle Modifications

    Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...
    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

    Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
    Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
    Antihypertensive Drugs: Vasodilators01:23

    Antihypertensive Drugs: Vasodilators

    Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
    Hypertension II: Pathophysiology01:29

    Hypertension II: Pathophysiology

    Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
    Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

    Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

    Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...